503941820 08/02/2016

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3988476

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MYREXIS, INC.	12/21/2012

RECEIVING PARTY DATA

Name:	ALZHEIMER'S INSTITUTE OF AMERICA, INC.
Street Address:	7837 PARALLEL PARKWAY
City:	KANSAS CITY
State/Country:	KANSAS
Postal Code:	66112

PROPERTY NUMBERS Total: 2

Property Type	Number
Patent Number:	7595401
Patent Number:	8476285

CORRESPONDENCE DATA

Fax Number: (609)896-1469

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 609-844-7427

Email: ipdocket@foxrothschild.com

Correspondent Name: FLYNN BARRISON
Address Line 1: FOX ROTHSCHILD LLP

Address Line 2: 997 LENOX DRIVE, BLDG. #3

Address Line 4: LAWRENCEVILLE, NEW JERSEY 08648

ATTORNEY DOCKET NUMBER:	147557.00001
NAME OF SUBMITTER:	OLGA AYALA
SIGNATURE:	/Olga Ayala/
DATE SIGNED:	08/02/2016

Total Attachments: 7

source=Myrexis_to_AIA_Assigmment#page1.tif source=Myrexis_to_AIA_Assigmment#page2.tif source=Myrexis_to_AIA_Assigmment#page3.tif source=Myrexis_to_AIA_Assigmment#page4.tif

> PATENT REEL: 039314 FRAME: 0583

503941820

source=Myrexis_to_AIA_Assigmment#page5.tif source=Myrexis_to_AIA_Assigmment#page6.tif source=Myrexis_to_AIA_Assigmment#page7.tif

EXHIBIT F

Patent Assignment

ASSIGNMENT

WHEREAS, MYREXIS, INC. (hereinafter "ASSIGNOR"), having a principal place of business at 305 Chipeta Way, Salt Lake City, Utah 84108, is the owner or co-owner of those certain patents and patent applications listed on the attached Exhibit A ("Patents");

WHEREAS, ALZHEIMER'S INSTITUTE OF AMERICA, INC. (hereinafter "ASSIGNEE"), having a principal place of business at 7837 Parallel Parkway, Kansas City KS 66112-2493 U.S.A. desires to acquire all of Assignors rights in the Patents;

NOW, THEREFORE, to all whom it may concern, be it known that, subject to the terms and conditions of the Confidential Settlement Agreement, Including Releases of Claims and Covenant Not To Sue (the "Agreement") duly entered into between the parties, for good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, ASSIGNOR has assigned and transferred unto ASSIGNEE, its successors, assigns, and legal representatives, all of its right, title, and interest in and obligations under:

- (a) the Patents;
- (b) all divisionals, continuations, and other patent applications claiming the benefit of or priority to any of (a);

ALZHEIMER'S INSTITUTE OF AMERICA, INC.

December 21, 2012

- (c) any patents granted upon any of (a) or (b); and
- (d) all extensions, reissues, and reexaminations of any of (a), (b), or (c).

IN TESTIMONY WHEREOF, ASSIGNOR and ASSIGNEE by their duly authorized representatives acting on their own free will have caused this instrument to be duly executed on the dates set forth below.

By: David W. LEYSTA	By: Mayanit. Cura
Name: DAVID W. GRYSTA	Name: Marjorie Curran
Title: Coo	Title: Corporate Secretary

Date:

MYREXIS, INC.

EXHIBIT A Patents

		HS	HSP90 Inhibitor Patents and Patent Applications	nd Patent Appl	cations		 IT
Docket Number	Country	Application Date	Application Number	Grant Date	Patent Number	Title	FN
10:10101/652550	US	06/30/2009	12/494917			THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER	ΡΔΤ
035759/10102:01	AU	05/14/2007	2007249194			THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER	<u>ı</u> I
035759/10103:01	CA	05/14/2007	2652263			THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER	
035759/10104:01	CN	05/14/2007	200780025733.9	05/04/2012	200780025733.9	THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER	
035759/10105:01	EP	05/14/2007	07762175.3			THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER	
035759/10106:01	HK	01/20/2010	10100581.3			THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER	1
035759/10107:01	N	05/14/2007	4602/KOLNP/2008			THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER	1
035759/10108:01	JP	05/14/2007	2009-510197			THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER	1
035759/10109:01	NZ	05/14/2007	572600	12/05/2011	572600	THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER	1
035759/10110:01	US	05/14/2007	11/748362	09/29/2009	7595401	THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER	1
035759/10111:01	US	08/23/2010	12/861721			THERAPEUTIC COMPOUNDS AND USES THEREOF	1
035759/10112:01	AU	11/14/2008	2008322503			THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS	<u> </u>
							_

035759/10124:01	035759/10123:01	035759/10121:01	035759/10120:01	035759/10119:01	035759/10118:01	035759/10117:01	035759/10116:01	035759/10115:01	035759/10114:01	035759/10113:01
US	WO	US	US	NZ	JP	Z	HK	EP	CX	CA
10/09/2009	02/24/2012	05/14/2012	05/14/2010	11/14/2008	11/14/2008	11/14/2008	04/01/2011	11/14/2008	11/14/2008	11/14/2008
12/577042	PCT/US2012/026593	13/470914	12/780828	586129	2010-534230	2148/KOLNP/2010	11103345.3	08849625.2	200880124620.9	2705579
09/13/2011										
8017780										
THERAPEUTIC COMPOUNDS AND USES THEREOF	PRODRUGS OF THERAPEUTIC COMPOUNDS	METHODS OF TREATING DISEASES, PHARMACEUTICAL COMPOSITIONS, AND PHARMACEUTICAL DOSAGE FORMS	THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS	THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS	THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS	THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS	THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS	THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS	THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS	THERAPEUTIC COMPOUNDS AND THEIR USE IN TREATING DISEASES AND DISORDERS

035759 035759	035759	035759		035759	035759	Docke	
035759/10304:01	10304:01		035759/10303:01	035759/10302:01	035759/10301:01	Docket Number	
	EP	CN	CA	BR	AU	Country	
	10/12/2010	10/12/2010	10/12/2010	10/12/2010	10/12/2010	Application Date	IKK
	10768665.1	201080056450.2	2777762	11 2012 008677 4	2010306927	Application Number	IKKε/TBK1 Inhibitor Patents and Patent Applications
						Grant Date	and Patent A ₁
						Patent Number	plications
AMINO-PYRIMIDINE	AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON	Title					

035759/10318:01	035759/10313:01	035759/10311:01	035759/10310:01	035759/10309:01	035759/10308:01	035759/10307:01
US	WO	US	NZ	MX	KR	JP
06/27/2012	04/12/2012	04/12/2012	10/12/2010	10/12/2010	10/12/2010	10/12/2010
61/665270	PCT/US2012/033384	13/445627	599826	MX/a/2012/004313	10-2012-7012283	2012-534299
COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF	COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF	AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF IKK EPSILON AND/OR TBK1	AMINO-PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON			

Docket Number Country App 035759/10402:01 US 12/0 035759/10403:01 US 09/1 035759/10411:01 PCT 06/2 035759/10412:01 US 06/2 035759/10415:01 AU 03/0 035759/10416:01 BR 03/0 035759/10419:01 CA 03/0 035759/10420:01 IN 03/0 035759/10421:01 JP 03/0					
US US US US US OF COUNTRY OF	NAM	—12°	d Patent Appli	cations	
US US US US II US II US IN IN	12/09/2011 6	61/568778		A STOCKED TO SELECT	COMPOUNDS AND THERAPEUTIC USES THEREOF
PCT US AU AU CN EPC IN		13/235221			THERAPEUTIC AND DIAGNOSTIC METHODS
US 1 US AU CA EPC IN		PCT/US2012/043376			COMPOUNDS AND THERAPEUTIC USES THEREOF
AU AU CA EPC IN		61/665297			COMPOUNDS AND THERAPEUTIC USES THEREOF
AU BR CA IN		13/601879			COMPOUNDS AND THERAPEUTIC USES THEREOF
BR CA IN	03/01/2011 2	2011223790			COMPOUNDS AND THERAPEUTIC USES THEREOF
CA CN EPC	03/01/2011 B	BR 11 2012 021806 9			COMPOUNDS AND THERAPEUTIC USES THEREOF
EPC IN	03/01/2011 2	2791680			COMPOUNDS AND THERAPEUTIC USES THEREOF
EPC IN	03/01/2011 2	201180022156.4			COMPOUNDS AND THERAPEUTIC USES THEREOF
JP		11751234.3			COMPOUNDS AND THERAPEUTIC USES THEREOF
JP	03/01/2011 8	8343/DELNP/2012			COMPOUNDS AND THERAPEUTIC USES THEREOF
	03/01/2011 J	JP			COMPOUNDS AND THERAPEUTIC USES THEREOF
035759/10422:01 MX 03/C	03/01/2011	MX/a/2012/010011			COMPOUNDS AND THERAPEUTIC USES THEREOF
035759/10423:01 NZ 03/C		601,788			COMPOUNDS AND THERAPEUTIC USES THEREOF
035759/10424:01 KR 03/01/2011		10-2012-7025575			COMPOUNDS AND THERAPEUTIC USES THEREOF

6

RECORDED: 08/02/2016

COMPOUNDS AND
THERAPEUTIC USES THEREOF